List of Excipients in API abrocitinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing abrocitinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | CIBINQO | abrocitinib | 0069-0235 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | 2034-02-19 |
| Pfizer Laboratories Div Pfizer Inc | CIBINQO | abrocitinib | 0069-0235 | CELLULOSE, MICROCRYSTALLINE | 2034-02-19 |
| Pfizer Laboratories Div Pfizer Inc | CIBINQO | abrocitinib | 0069-0235 | FERRIC OXIDE RED | 2034-02-19 |
| Pfizer Laboratories Div Pfizer Inc | CIBINQO | abrocitinib | 0069-0235 | HYPROMELLOSE | 2034-02-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for abrocitinib
Excipient focus: ANHYDROUS DIBASIC CALCIUM PHOSPHATE
abrocitinib drug variants containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing ANHYDROUS DIBASIC CALCIUM PHOSPHATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
abrocitinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
abrocitinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
abrocitinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
abrocitinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
abrocitinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
abrocitinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A
abrocitinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
abrocitinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
abrocitinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | abrocitinib | 0069-0235 |
| US Pharmaceuticals | abrocitinib | 63539-236 |
| >Company | >Ingredient | >NDC |
abrocitinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
